Your browser doesn't support javascript.
loading
Protective effects of vitamin E on chemotherapy-induced peripheral neuropathy: a meta-analysis of randomized controlled trials.
Eum, Seenae; Choi, Hye-Duck; Chang, Min-Jung; Choi, Ho-Chun; Ko, Young-Jin; Ahn, Jeong-Soo; Shin, Wan-Gyoon; Lee, Ju-Yeun.
Afiliación
  • Eum S; Department of Clinical Pharmacy, College of Pharmacy, Seoul National University, South Korea.
  • Choi HD; Department of Clinical Pharmacy, College of Pharmacy, Seoul National University, South Korea.
  • Chang MJ; College of Pharmacy, Yonsei University, Gyeonggi-do, South Korea.
  • Choi HC; Department of Family Medicine, Seoul National University Hospital, South Korea.
  • Ko YJ; Department of Family Medicine, Seoul National University Hospital, South Korea.
  • Ahn JS; Department of Family Medicine, Seoul National University Hospital, South Korea.
  • Shin WG; Department of Clinical Pharmacy, College of Pharmacy, Seoul National University, South Korea.
  • Lee JY; College of Pharmacy, Institute of Pharmaceutical Science and Technology, Hanyang University, Gyeonggi-do, South Korea.
Int J Vitam Nutr Res ; 83(2): 101-11, 2013.
Article en En | MEDLINE | ID: mdl-24491883
PURPOSE: This study aimed to investigate the neuroprotective effects of vitamin E for preventing chemotherapy-induced peripheral neuropathy (CIPN). METHODS: A comprehensive search from 1973 through July 2011 identified randomized controlled trials (RCTs) that reported the preventive effects of vitamin E on CIPN. The relative risk (RR) of CIPN with vitamin E supplementation, compared with placebo, was assessed with the Bayesian random effect model and expressed as RR with a 95 % credible-interval (CrI). Bayesian outcome probabilities were calculated as the probability (P) of RR < 1. RESULTS: Five RCTs, involving 319 patients, were identified. Upon pooling these RCTs, vitamin E supplementation (300 - 600 mg/day) had a significant effect on CIPN prevention (RR 0.43; 95 % CrI 0.10 - 1.00, P = 97.5 %). Subgroup analysis by chemotherapeutic agent type was only available for cisplatin and showed that vitamin E supplementation significantly reduced the incidence of CIPN (RR 0.26; 95 % CrI 0.06 - 0.89, P = 98.1 %). Furthermore, there were no adverse effects caused by vitamin E supplementation in any of the RCTs. CONCLUSION: Available data included in this meta-analysis show that vitamin E supplementation might significantly prevent CIPN. Currently, however, the data are insufficient to confidently conclude the true value. Large-scale, rigorously designed RCTs are needed to confirm the role of vitamin E supplementation in CIPN prevention.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vitamina E / Ensayos Clínicos Controlados Aleatorios como Asunto / Enfermedades del Sistema Nervioso Periférico / Antineoplásicos / Antioxidantes Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Int J Vitam Nutr Res Año: 2013 Tipo del documento: Article País de afiliación: Corea del Sur

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vitamina E / Ensayos Clínicos Controlados Aleatorios como Asunto / Enfermedades del Sistema Nervioso Periférico / Antineoplásicos / Antioxidantes Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Int J Vitam Nutr Res Año: 2013 Tipo del documento: Article País de afiliación: Corea del Sur